tiprankstipranks
Trending News
More News >

Aditxt Ends Agreement with Appili Therapeutics

Story Highlights
Aditxt Ends Agreement with Appili Therapeutics

Confident Investing Starts Here:

Aditxt ( (ADTX) ) has provided an announcement.

Aditxt, Inc. announced the termination of its Arrangement Agreement with Appili Therapeutics, Inc., effective May 31, 2025. The decision was made after determining that the agreement was no longer strategically aligned with Aditxt’s goals, eliminating approximately $16 million in closing obligations. This move reflects Aditxt’s strategic realignment and could impact its market positioning and stakeholder interests.

More about Aditxt

Aditxt, Inc. is a social innovation platform focused on accelerating promising health innovations. The company operates an ecosystem involving research institutions, industry partners, and shareholders to drive its mission of making promising innovations possible. Aditxt currently has programs focused on immune health and precision health and plans to introduce a new program dedicated to women’s health through a merger with Evofem Biosciences, Inc.

Average Trading Volume: 2,991,220

Technical Sentiment Signal: Strong Sell

Current Market Cap: $3.52M

See more insights into ADTX stock on TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App